# A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Study · id `cardio:ct-nct04157751` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04157751](<https://clinicaltrials.gov/study/NCT04157751>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04157751

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 530 participants.

## Technical summary

Registry record NCT04157751. Randomized; double masking; primary purpose treatment. Start 2020-05-18 (actual); primary completion 2021-05-28 (actual). Results posted on 2022-06-06.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 530 participants (enrolled count; ClinicalTrials.gov record NCT04157751, source copy `cardio:ctgov-nct04157751-2022-07-19`, retrieved 2026-10-26)
- Started: 2020-05-18 (actual) (ClinicalTrials.gov record NCT04157751, source copy `cardio:ctgov-nct04157751-2022-07-19`, retrieved 2026-10-26)
- Primary completion: 2021-05-28 (actual) (ClinicalTrials.gov record NCT04157751, source copy `cardio:ctgov-nct04157751-2022-07-19`, retrieved 2026-10-26)
- Completion: 2021-06-02 (actual) (ClinicalTrials.gov record NCT04157751, source copy `cardio:ctgov-nct04157751-2022-07-19`, retrieved 2026-10-26)
- Results first posted: 2022-06-06 (ClinicalTrials.gov record NCT04157751, source copy `cardio:ctgov-nct04157751-2022-07-19`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; China; Czechia; Denmark; Germany; Hungary; Italy; Japan; Netherlands; Norway; Poland; Spain; Sweden (ClinicalTrials.gov record NCT04157751, source copy `cardio:ctgov-nct04157751-2022-07-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04157751-2022-07-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
- Condition: Heart Failure
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo to Empagliflozin
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (`cardio:pubmed-35228754`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial (`cardio:pubmed-35377706`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE (`cardio:pubmed-37540060`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE (`cardio:pubmed-41793401`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: bc4cb3157b204d257ffa6686759560bf7b5baac8b539231f100fe4b6973b834a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
